



COLORADO

Department of Health Care
Policy & Financing

MINUTES OF THE MEETING OF THE COLORADO MEDICAID P&T COMMITTEE

Department of Healthcare Policy and Financing
225 E. 16th Avenue, 1st Floor Conference Room

January 6, 2015

1. Call to Order

A quorum being present, S. Grubb officially called the meeting to order at 13:07.

2. Roll Call

The Board Coordinator called the roll. There were sufficient members for a quorum with eight members participating and three members excused. Mr. Fox and Dr. Young participated by telephone conference call.

A. Members Present

Lynn Parry, MD
Patricia Lanius, RPh
Jennifer Hyer, MD
Leslie Moldauer, MD, MBA
Roy J. Durbin Jr., MD
Katy Trinkley, PharmD
Andrew Davis, PharmD, MBA
Deanna Tolman, FNP
Laura Rang, RPh
James Feinstein, MD
Steven Russell, MD
Kimberley Jackson, DO

B. Members Excused

None



C. Staff Present

Swanee Grubb, PharmD
Kelli Metz, PharmD
Nila Mahyari, PharmD
Erin Valenciano, Pharmacy intern

3. Announcements

Committee member introductions were made as there was 5 new committee members.

P. Lanius nominated L. Parry for chairperson. J. Hyer seconded. All in favor. Motion passed with no audible dissent. J. Hyer nominated Patricia Lanius for vice-chairperson. L. Moldauer seconded. All in favor. Motion passed with no audible dissent.

4. Approval of Minutes

L. Parry asked for approval of the minutes from the October 7, 2014 meeting. The minutes were approved with no audible dissent.

5. Department Updates

S. Grubb gave an update on the PDL changes for the following:

- Antiherpetics
- Fluoroquinolones
- Antiemetics
- New Generation Antidepressants
- Antiplatelets
- Pancreatic enzymes
- Proton Pump Inhibitors
- Pulmonary Arterial Hypertension Therapies
- Targeted Immune Modulators for Rheumatoid Arthritis
- Triptans

S. Grubb gave updates about the prior authorization helpdesk call statistics. The prior authorization numbers from the previous month were about the same as usual. This being about 84% approvals and 16% denials.

6. Rules

S. Grubb presented changes the Department made to the P&T Policy and Procedures including changing the term manufacturer to stakeholder throughout the testimony section of the document. The Department also added a policy regarding



factual inaccuracies presented during the meeting. P. Lanius made a motion to approve changes to the document. D. Tolman seconded. All in favor motion passed with no audible dissent.

L. Parry presented guidelines for manufacturer and public presentations. Oral presentations will be restricted to products that are being reviewed for PDL status. Presentations will be limited to a maximum of three minutes per representative per drug product. Representatives will be called to present in the order in which they signed in by drug class. Presentations must be limited to verbal comments. No visual aids, other than designated handouts, are permitted. Presentations should follow the one page summary that was submitted to the Department. The audience will be considered a reference tool for the committee. The committee will discuss topics and audience participation will be allowed if P&T members ask for clarification. S. Grubb disseminated recently received public comments to the committee members.

A. DRUG CLASSES FOR REVIEW

1. L. Parry moved to discuss Alzheimer's agents. With no speakers present S. Grubb gave FDA updates, utilization information, and current preferred products. J. Hyer made the motion that one NMDA antagonist be included as preferred. L. Moldauer seconded. No discussion. The motion passed with no audible dissent. L. Moldauer made the motion that at least one cholinesterase inhibitor should be considered for addition to the formulary with consideration given to multiple dosage forms and a better side effect profile. L. Hyer seconded the motion. The motion passed with no audible dissent. J. Hyer made the motion that all cholinesterase inhibitors are considered to have similar efficacy. K. Trinkley seconded. No discussion. The motion passed with no audible dissent. R. Durbin made a motion that at least one product be available with once daily dosing due to caregiver issues including one NMDA inhibitor. K. Jackson seconded. L. Moldauer made a friendly amendment for and at least one cholinesterase inhibitor which was accepted. R. Durbin discussed patients having trouble remembering bid and decreased adherence. Final motion that at least one product be available with once daily dosing due to caregiver issues including one NMDA inhibitor and at least one cholinesterase inhibitor. The motion passed with no audible dissent. K. Trinkley made a motion to give preference to a cholinesterase inhibitor with an indication for severe Alzheimer's disease. J. Hyer seconded. No discussion. The motion passed with no audible dissent.
2. L. Parry moved to discuss Atypical Antipsychotics. L. Moldauer recuses herself due to conflict of interest with Abilify. L. Laird, from Sunovion spoke about Latuda. He spoke about indication, warnings, studies, and use in pregnancy. C. Henderson the MSL with Otsuka spoke regarding Abilify.



Abilify has a new indication for Tourette's for ages 6 and up. Karen Nguyen from Actavis spoke about Saphris. She stated that it has a favorable weight gain profile. S. Grubb gave FDA updates, utilization information, and current preferred products. R. Durbin made the motion for at least one orally disintegrating tablet in children and at least one for adults be on the preferred drug list. D. Tolman seconded. P. Lanius made a friendly amendment to use pediatric which was accepted. Final motion was for at least one orally disintegrating tablet in children and at least one for adults be on the preferred drug list. L. Moldauer abstained. The motion passed with no audible dissent. F. Feinstein made the motion that at least one agent be preferred that is approved in children down to six years of age. J. Hyer seconded. L. Moldauer abstained. The motion passed with no audible dissent. J. Hyer made the motion that clozapine be considered preferred due to its proven efficacy in specific populations. K. Trinkley seconded. No discussion. L. Moldauer abstained. The motion passed with no audible dissent. K. Jackson made the motion that at least two agents should be on the preferred list that have been shown to be weight neutral. J. Feinstein seconded. No discussion. L. Moldauer abstained. The motion passed with no audible dissent. J. Hyer made the motion at least one agent with sedating properties be preferred. P. Lanius seconded. L. Moldauer abstained. The motion passed with no audible dissent. J. Hyer made the motion at least one agent known with lower risk of EPS side effects including tardive dyskinesia, should be preferred. K. Jackson seconded. No discussion. L. Moldauer abstained. The motion passed with no audible dissent. J. Hyer made the motion that at least one pregnancy category B be preferred. K. Jackson seconded. L. Moldauer abstained. The motion passed with no audible dissent. K. Jackson made the motion that at least one agent with no case reports of QTC prolongation be available. J. Hyer seconded. No discussion. L. Moldauer abstained. The motion passed with no audible dissent. The committee made a comment to the DUR board that all women of childbearing age should be counseled regarding continuation of their medication.

3. L. Parry moved to discuss Growth Hormones. R. Hansen from Pfizer spoke about Genotropin. J. Patel from Novo Nordisk spoke regarding Norditropin. M. Fuzeo from US BioServices a local specialty pharmacy. She spoke how patient like the disposable pens. The room temperature stability has been helpful. S. Grubb gave FDA updates, utilization information, and current preferred products. P. Lanius made the motion to consider the ease of use, storage, and handling requirements when selecting preferred products. J. Feinstein seconded. The motion passed with no audible dissent. P. Lanius made the motion that due to safety concerns, the committee strongly urges DUR to analyze the appropriate use. A. Davis made a friendly amendment to



say appropriate use. D. Tolman seconded the motion. The motion passed with no audible dissent.

4. L. Parry moved to discuss Insulins. R. Owen and S. Hoops from the Barbara Davis Center spoke about wanting open access because patients and parents are afraid to switch insulin and do not follow provider instructions so their A1C's have increased. S. Grubb gave FDA updates, utilization information, and current preferred products. There was lengthy discussion regarding efficacy due to patient noncompliance and allowing multiple products in each category. K. Trinkley made a motion that at least two available long acting agents that are also available in pen and vial form be preferred. R. Durbin seconded the motion. The motion passed with no audible dissent. K. Trinkley made a motion that at least two rapid acting and also intermediate acting products if available also in pen and vial form are available. K. Jackson seconded. The motion passed with no audible dissent. K. Trinkley made a motion that regular insulin needs to be available for the pregnant population. P. Lanius seconded. Motion passed with no audible dissent. K. Jackson made a motion that the committee recommends that due to testimony the 30 day failure be evaluated. K. Trinkley seconded. The motion passed with no audible dissent. K. Jackson made the motion that multiple options for insulin mixes are available in pen and vial form. K. Trinkley seconded. The motion passed with no audible dissent.
5. L. Parry moved to discuss Intranasal Corticosteroids. With no speakers present S. Grubb gave FDA updates, utilization information, and current preferred products. J. Hyer made the motion that all products were comparable in safety and efficacy, and that special consideration should be given to agent's doses down to age 2. D. Tolman seconded the motion. The motion passed with no audible dissent.
6. L. Parry moved to discuss Leukotriene Modifiers. With no speakers present S. Grubb gave FDA updates, utilization information, and current preferred products. K. Jackson made the motion that all products are comparable for efficacy. K. Trinkley seconded. No discussion. The motion passed with no audible dissent. P. Lanius made the motion that special consideration should be given to safety and flexibility of dosing with respect to pediatric dosing. J. Feinstein seconded. The motion passed with no audible dissent. There was discussion about how nothing stands out with regards to safety issues.
7. L. Parry moved to discuss Multiple Sclerosis agents. Carol Kicklighter for Novartis spoke about Gilenya. L. Weedon from Biogen spoke regarding Avonex, Plegridy, and Tecfidera. L. Parry made a motion that an oral agent be available if there is a significant deterioration in clinical presentation regardless of previous experiences with interferons or Copaxone. L. Rang



made a friendly amendment to add Copaxone. K. Jackson seconded. The motion passed with no audible dissent. K. Jackson made the motion that due to issues of compliance both doses of Copaxone should be available. K. Trinkley seconded. 1 nay. The motion passed. K. Jackson made the motion that at least one interferon beta 1a and one interferon 1b be preferred. P. Lanius seconded. The motion passed with no audible dissent.

- 8. L. Parry moved to discuss Ophthalmic Allergy agents. S. Edelhauser from Alcon spoke regarding Pataday. S. Grubb gave FDA updates, utilization information, and current preferred products. J. Feinstein made a motion to include a product of pediatric age indications. K. Jackson seconded. The motion passed with no audible dissent. K. Jackson made a motion that since the safety and efficacy of these agents are similar at least two agents be preferred. K. Trinkley seconded. The motion passed with no audible dissent.
- 9. L. Parry moved to discuss Sedative/Hypnotics (non-benzodiazepine). R. Gualtieri spoke regarding the new product Belsomra and its new mechanism of action. S. Grubb gave FDA updates, utilization information, and current preferred products. L. Moldauer made the motion that one product for sleep maintenance be approved. 6 I’s, 4 nay, 2 abstained. The motion passed.
- 10. L. Parry moved to discuss Statins/Statin Combinations. With no speakers present S. Grubb gave FDA updates, utilization information, and current preferred products. J. Feinstein made the motion of at least one product be considered with pediatric indication be included as preferred. K. Jackson seconded. The motion passed with no audible dissent. K. Jackson made the motion that one product with reduced drug interaction risk be included as preferred. L. Parry seconded. The motion passed with no audible dissent. K. Jackson made the motion to include two high potency statins defined as >50% reduction in LDL. K. Trinkley seconded the motion. The motion passed with no audible dissent.

7. The meeting was adjourned at 1635.

By: _____

Lynn Parry, MD, Chair

Date: _____

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Committee Coordinator at 303- 866-3614 or



swaniee.grubb@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting.

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf

